CY1114853T1 - Μεθοδοι χορηγησης ν-(5-tert-βουτυλ-ισοξαζολυλ-3-υλο)-ν'-{4-[7-(2-μορφολιν-4-υλο-αιθοξυ)ιμιδαζο[2,1-β][1,3]βενζοθειαζολ-2-υλο]φαινυλ]ουριας για αντιμετωπιση υπερπλαστικων νοσων - Google Patents
Μεθοδοι χορηγησης ν-(5-tert-βουτυλ-ισοξαζολυλ-3-υλο)-ν'-{4-[7-(2-μορφολιν-4-υλο-αιθοξυ)ιμιδαζο[2,1-β][1,3]βενζοθειαζολ-2-υλο]φαινυλ]ουριας για αντιμετωπιση υπερπλαστικων νοσωνInfo
- Publication number
- CY1114853T1 CY1114853T1 CY20131101036T CY131101036T CY1114853T1 CY 1114853 T1 CY1114853 T1 CY 1114853T1 CY 20131101036 T CY20131101036 T CY 20131101036T CY 131101036 T CY131101036 T CY 131101036T CY 1114853 T1 CY1114853 T1 CY 1114853T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- morpholin
- imidazo
- isoxazolyl
- ethoxy
- Prior art date
Links
- -1 5-TERT-BUTYL-ISOXAZOLYL-3-YL Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002485 urinary effect Effects 0.000 title 1
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 abstract 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Inorganic Chemistry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US258307P | 2007-11-08 | 2007-11-08 | |
| US580307P | 2007-12-07 | 2007-12-07 | |
| US9867608P | 2008-09-19 | 2008-09-19 | |
| US11206008P | 2008-11-06 | 2008-11-06 | |
| EP08847113.1A EP2205244B1 (en) | 2007-11-08 | 2008-11-07 | Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy-)imidazo-[2,1-b]-[1,3]-benzothiazol-2-yl]-phenyl}urea to treat proliferative disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114853T1 true CY1114853T1 (el) | 2016-12-14 |
Family
ID=40262072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131101036T CY1114853T1 (el) | 2007-11-08 | 2013-11-21 | Μεθοδοι χορηγησης ν-(5-tert-βουτυλ-ισοξαζολυλ-3-υλο)-ν'-{4-[7-(2-μορφολιν-4-υλο-αιθοξυ)ιμιδαζο[2,1-β][1,3]βενζοθειαζολ-2-υλο]φαινυλ]ουριας για αντιμετωπιση υπερπλαστικων νοσων |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7968543B2 (https=) |
| EP (2) | EP2596795A1 (https=) |
| JP (2) | JP5645667B2 (https=) |
| KR (2) | KR101578481B1 (https=) |
| CN (1) | CN101835472A (https=) |
| AR (1) | AR069244A1 (https=) |
| AU (1) | AU2008325141B2 (https=) |
| CA (1) | CA2696807C (https=) |
| CY (1) | CY1114853T1 (https=) |
| DK (1) | DK2205244T3 (https=) |
| ES (1) | ES2436266T3 (https=) |
| HR (1) | HRP20131083T1 (https=) |
| MX (1) | MX2010002396A (https=) |
| PL (1) | PL2205244T3 (https=) |
| PT (1) | PT2205244E (https=) |
| SI (1) | SI2205244T1 (https=) |
| TW (1) | TW200924756A (https=) |
| WO (1) | WO2009061446A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2422890T3 (es) * | 2006-03-17 | 2013-09-16 | Ambit Biosciences Corporation | Compuestos de imidazolotiazol para el tratamiento de enfermedades proliferativas |
| CA2696776C (en) * | 2007-09-19 | 2015-12-15 | Ambit Biosciences Corporation | Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
| CN102438588B (zh) | 2009-03-23 | 2015-04-01 | 埃姆比特生物科学公司 | 使用联合治疗法治疗疾病的方法 |
| SMT202000092T1 (it) * | 2009-05-14 | 2020-05-08 | Ambit Biosciences Corp | Formulazione essiccata a spruzzo o liofilizzata di ac220 |
| CN104447801A (zh) | 2009-11-05 | 2015-03-25 | 埃姆比特生物科学公司 | 用于制备咪唑并[2,1-b][1,3]苯并噻唑衍生物的方法 |
| US9109227B2 (en) | 2010-01-05 | 2015-08-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | FLT3 receptor antagonists for the treatment or the prevention of pain disorders |
| UY33472A (es) | 2010-06-30 | 2012-01-31 | Novartis Ag | ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. |
| CN103172648B (zh) * | 2011-12-20 | 2016-05-25 | 上海迪诺医药科技有限公司 | 三杂环衍生物、制备方法及应用 |
| JP6116847B2 (ja) * | 2012-10-01 | 2017-04-19 | アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | シクロデキストリンとの混合体を含有する錠剤 |
| CN104513252B (zh) * | 2013-09-26 | 2017-11-10 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
| CN107001283B (zh) | 2014-07-31 | 2021-05-25 | 国家健康与医学研究院 | Flt3受体拮抗剂 |
| KR20250025516A (ko) | 2014-12-22 | 2025-02-21 | 젠자임 코포레이션 | 포유류 세포의 배양 방법 |
| JP6564449B2 (ja) | 2015-02-20 | 2019-08-21 | 第一三共株式会社 | がんの併用治療法 |
| EP3269367B1 (en) * | 2015-03-11 | 2020-10-07 | Riken | Therapeutic agent for intractable leukemia |
| EP3254698A1 (en) | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
| WO2018211018A1 (en) | 2017-05-17 | 2018-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flt3 inhibitors for improving pain treatments by opioids |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2021180008A1 (zh) * | 2020-03-11 | 2021-09-16 | 暨南大学 | 含脲结构的三芳环化合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US233906A (en) * | 1880-11-02 | Combined stirrer and thermometer | ||
| US233903A (en) * | 1880-11-02 | Velocipede | ||
| US994635A (en) * | 1911-01-10 | 1911-06-06 | Harry C Buhoup | Car-truck. |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| ES2422890T3 (es) | 2006-03-17 | 2013-09-16 | Ambit Biosciences Corporation | Compuestos de imidazolotiazol para el tratamiento de enfermedades proliferativas |
| CA2696776C (en) * | 2007-09-19 | 2015-12-15 | Ambit Biosciences Corporation | Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
-
2008
- 2008-11-07 CA CA2696807A patent/CA2696807C/en active Active
- 2008-11-07 KR KR1020107006419A patent/KR101578481B1/ko active Active
- 2008-11-07 PT PT88471131T patent/PT2205244E/pt unknown
- 2008-11-07 EP EP12197285.5A patent/EP2596795A1/en not_active Withdrawn
- 2008-11-07 SI SI200831093T patent/SI2205244T1/sl unknown
- 2008-11-07 HR HRP20131083AT patent/HRP20131083T1/hr unknown
- 2008-11-07 MX MX2010002396A patent/MX2010002396A/es active IP Right Grant
- 2008-11-07 KR KR1020157024194A patent/KR20150105494A/ko not_active Ceased
- 2008-11-07 PL PL08847113T patent/PL2205244T3/pl unknown
- 2008-11-07 TW TW097143281A patent/TW200924756A/zh unknown
- 2008-11-07 AR ARP080104899A patent/AR069244A1/es unknown
- 2008-11-07 DK DK08847113.1T patent/DK2205244T3/da active
- 2008-11-07 CN CN200880112433A patent/CN101835472A/zh active Pending
- 2008-11-07 WO PCT/US2008/012539 patent/WO2009061446A1/en not_active Ceased
- 2008-11-07 US US12/267,321 patent/US7968543B2/en active Active
- 2008-11-07 ES ES08847113T patent/ES2436266T3/es active Active
- 2008-11-07 JP JP2010533098A patent/JP5645667B2/ja active Active
- 2008-11-07 AU AU2008325141A patent/AU2008325141B2/en active Active
- 2008-11-07 EP EP08847113.1A patent/EP2205244B1/en active Active
-
2013
- 2013-11-21 CY CY20131101036T patent/CY1114853T1/el unknown
-
2014
- 2014-06-11 JP JP2014120238A patent/JP2014221765A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20131083T1 (hr) | 2013-12-20 |
| DK2205244T3 (da) | 2013-11-25 |
| TW200924756A (en) | 2009-06-16 |
| US20090123418A1 (en) | 2009-05-14 |
| JP2014221765A (ja) | 2014-11-27 |
| PL2205244T3 (pl) | 2014-01-31 |
| AU2008325141A1 (en) | 2009-05-14 |
| KR20100075853A (ko) | 2010-07-05 |
| KR101578481B1 (ko) | 2015-12-17 |
| EP2596795A1 (en) | 2013-05-29 |
| AU2008325141B2 (en) | 2014-03-20 |
| AR069244A1 (es) | 2010-01-06 |
| JP5645667B2 (ja) | 2014-12-24 |
| KR20150105494A (ko) | 2015-09-16 |
| ES2436266T3 (es) | 2013-12-30 |
| WO2009061446A1 (en) | 2009-05-14 |
| CA2696807C (en) | 2017-11-28 |
| PT2205244E (pt) | 2013-11-26 |
| US7968543B2 (en) | 2011-06-28 |
| JP2011503063A (ja) | 2011-01-27 |
| SI2205244T1 (sl) | 2013-12-31 |
| CN101835472A (zh) | 2010-09-15 |
| MX2010002396A (es) | 2010-04-01 |
| CA2696807A1 (en) | 2009-05-14 |
| EP2205244A1 (en) | 2010-07-14 |
| EP2205244B1 (en) | 2013-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1114853T1 (el) | Μεθοδοι χορηγησης ν-(5-tert-βουτυλ-ισοξαζολυλ-3-υλο)-ν'-{4-[7-(2-μορφολιν-4-υλο-αιθοξυ)ιμιδαζο[2,1-β][1,3]βενζοθειαζολ-2-υλο]φαινυλ]ουριας για αντιμετωπιση υπερπλαστικων νοσων | |
| CY1122765T1 (el) | Ξηρανθεισα με ψεκασμο συνθεση αc220 | |
| EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
| CY1124432T1 (el) | Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη | |
| BRPI0413427A (pt) | derivados de piridilpirrol ativos como inibidores da cinase | |
| EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
| EA200600820A1 (ru) | Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина | |
| LU93321I2 (fr) | Ibrutinib, ou un sel pharmaceutiquement acceptable de celui-ci | |
| MXPA06000302A (es) | Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
| DE60030844D1 (de) | Kombinationen von formoterol und tiotropium-salz | |
| AR023972A1 (es) | Composiciones de medicamentos a base de compuestos anticolinergicamente activos y beta-mimeticos | |
| CZ309247B6 (cs) | 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru | |
| AR034213A1 (es) | Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv | |
| CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
| GB0211649D0 (en) | Organic compounds | |
| ATE369355T1 (de) | Pyrimidinamid derivate und deren verwendung | |
| EA200401317A1 (ru) | Композиции и способы дозирования липосом определенных размеров для лечения или предотвращения заболевания | |
| BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
| CY1108421T1 (el) | Η χρηση σκευασματων μελοξικαμης στην κτηνιατρικη | |
| CY1117583T1 (el) | Στερεες μορφες περιλαμβανοντας ν-(5-τριτοταγες-βουτυλ-ισοξαζολ-3-υλ)-ν΄-{4-[7-(2-μορφολιν-4-υλ-αιθοξυ)ιμιδαζο[2,1-β][1,3]βενζοθειαζολ-2-υλ]φαινυλ}ουρια,συνθεσεις εξ΄ αυτης, και χρησεις μετ΄ αυτης | |
| CY1113670T1 (el) | Φαρμακευτικη συνθεση για τη θεραπεια της υπερδραστηριας ουροδοχου κυστης | |
| CY1119790T1 (el) | Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας | |
| NZ801473A (en) | Lactam-modified polypeptide compounds | |
| EA200600817A1 (ru) | Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты) | |
| EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат |